Genetically modified cornea safely and effectively prevents rejection post-transplantation

April 12, 2018, Mary Ann Liebert, Inc
Credit: Mary Ann Liebert, Inc., publishers

Researchers engineered a donor cornea, introducing two genes intended to prevent new blood vessel formation following transplantation, and have shown this novel approach to be safe, well tolerated, and effective at reducing the risk of tissue rejection in a high-risk rabbit model. These conclusive findings support angiogenesis as a valid target for treatment to prevent corneal graft rejection in high-risk patients, accord-ing to the study published in Human Gene Therapy.

Tim Stout, Baylor College of Medicine (Houston, TX), Scott Ellis, Oxford BioMedica (Ox-ford, U.K.) and coauthors from Baylor, Oxford Biomedica, and Oregon Health and Scienc-es University (Portland) describe the study design, the outcomes, and the implications of their results in the article entitled "Safety and Efficacy of OXB-202, a Genetically Engineered Tissue Therapy for the Prevention of Rejection in High Risk Corneal Transplant Patients." The researchers used a lentiviral vector to transfer the for the human proteins endostatin and angiostatin into the donor corneas. These secreted proteins inhibit vasculari-zation, helping to prevent an immune reaction to the transplanted tissue and rejection of the cornea.

"The work from Drs. Stout and Ellis and their colleagues represents yet another example of how gene therapy for disorders of the eye has led the way in clinical translation," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "Gene modification of corneal transplants could provide a unique approach to filling a pressing unmet medical need."

Explore further: Positive clinical trial results on gene transfer to treat macular degeneration

More information: Naghmeh Fouladi et al, Safety and Efficacy of OXB-202, a Genetically Engineered Tissue Therapy for the Prevention of Rejection in High-Risk Corneal Transplant Patients, Human Gene Therapy (2018). DOI: 10.1089/hum.2017.184

Related Stories

Positive clinical trial results on gene transfer to treat macular degeneration

October 20, 2016
The long-term safety of gene transfer to treat neovascular age-related macular degeneration (NVAMD), and the production of two therapeutic proteins encoded by those genes for at least 2.5 years in the eyes of patients with ...

New work from Ron Crystal's lab on treating hereditary adrenal disorders

March 29, 2018
A new study has definitively shown that a single treatment with gene therapy using adeno-associated viral (AAV) vector gene delivery to replace the defective gene responsible for congenital adrenal hyperplasia (CAH) will ...

New technique may prevent graft rejection in high-risk corneal transplant patients

May 1, 2017
Treating donor corneas with a cocktail of molecules prior to transplanting to a host may improve survival of grafts and, thus, outcomes in high-risk corneal transplant patients, according to a new study led by researchers ...

Gene delivery to the lung can treat broad range of diseases within and beyond the lung

January 25, 2017
Targeting therapeutic genes to the lungs offers the potential to manage serious lung diseases that do not respond to other forms of treatment and to use the lungs as metabolic factories to produce therapeutic proteins for ...

Safety of gene transfer to treat heart failure supports further clinical development

June 6, 2017
Based on the encouraging safety data that has emerged from multiple clinical trials that used different gene transfer approaches to improve heart function in patients suffering from heart failure with reduced ejection fraction, ...

Gene delivery of drugs directly into arthritic joints is making the leap to patients

January 22, 2018
Localized gene delivery to diseased joints to achieve sustained drug production at the site of osteoarthritis or rheumatoid arthritis is gaining momentum, with clinical trials underway in the U.S. and the first arthritis ...

Recommended for you

Variants in non-coding DNA contribute to inherited autism risk

April 19, 2018
In recent years, researchers have firmly established that gene mutations appearing for the first time, called de novo mutations, contribute to approximately one-third of cases of autism spectrum disorder (ASD). In a new study, ...

Researchers discover link between gene variation and language

April 18, 2018
What shapes the basic features of a language?

Natural selection still at work in humans

April 18, 2018
Evolution has shaped the human race, with University of Queensland researchers finding signatures of natural selection in the genome that influence traits associated with fertility and heart function.

Gene therapy for beta-thalassemia safe, effective in people

April 18, 2018
In a powerful example of bench-to-bedside science showing how observations made in the lab can spark life-altering therapies in clinic, an international team of clinician-investigators has announced that gene therapy for ...

Potential lines of attack against prostate cancer

April 17, 2018
Researchers from The University of East Anglia (UEA) have contributed to the world's largest study into genes that drive prostate cancer – identifying 80 molecular weaknesses that could be targeted by drugs to treat the ...

Epstein-Barr virus linked to seven serious diseases

April 16, 2018
A far-reaching study conducted by scientists at Cincinnati Children's reports that the Epstein-Barr virus (EBV)—best known for causing mononucleosis—also increases the risks for some people of developing seven other major ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.